









市场行情
/
股票
/
nasdaq-krys
/

Krystal Biotech Inc

KRYS

240.800USD

+7.430+3.18%

收盘 12/19, 16:00（美东）报价延迟15分钟

6.98B总市值

34.91市盈率 TTM



Krystal Biotech Inc

240.800

+7.430+3.18%

概览公司财务分析

概览

公司

财务

分析

关于 Krystal Biotech Inc 公司

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

Krystal Biotech Inc简介



公司代码KRYS

公司名称Krystal Biotech Inc

上市日期Sep 20, 2017

CEOKrishnan (Krish S)

员工数量275

证券类型Ordinary Share

年结日Sep 20

公司地址2100 Wharton St Ste 701

城市PITTSBURGH

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编15203

电话14125865830

网址https://www.krystalbio.com/

公司代码KRYS

上市日期Sep 20, 2017

CEOKrishnan (Krish S)

Krystal Biotech Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Krish S. Krishnan

Chairman of the Board, President, Chief Executive Officer

1.62M

-1.82%

Ms. Suma M. Krishnan

President - Research and Development, Founder, Director

1.55M

-1.58%

Mr. Dino A. Rossi

Independent Director

78.69K

Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.

Independent Director

Mr. Kirti Ganorkar

Independent Director

Mr. Daniel S. Janney

Lead Independent Director

Ms. Catherine Mazzacco

Independent Director

Dr. Everett Rand Sutherland, M.D.

Independent Director

Mr. Julian S. Gangolli

Independent Director

Ms. Meg Dodge

Investor Relations

名称

名称/职务

职务

持股

持股变动

Mr. Krish S. Krishnan

Chairman of the Board, President, Chief Executive Officer

1.62M

-1.82%

Ms. Suma M. Krishnan

President - Research and Development, Founder, Director

1.55M

-1.58%

Mr. Dino A. Rossi

Independent Director

78.69K

Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.

Independent Director

Mr. Kirti Ganorkar

Independent Director

Mr. Daniel S. Janney

Lead Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月21日周五

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

14.95%

BlackRock Institutional Trust Company, N.A.

12.07%

The Vanguard Group, Inc.

9.61%

Avoro Capital Advisors LLC

9.58%

Krishnan (Krish S)

5.58%

其他

48.21%

持股股东

占比

Fidelity Management & Research Company LLC

14.95%

BlackRock Institutional Trust Company, N.A.

12.07%

The Vanguard Group, Inc.

9.61%

Avoro Capital Advisors LLC

9.58%

Krishnan (Krish S)

5.58%

其他

48.21%

股东类型

持股股东

占比

Investment Advisor

53.56%

Investment Advisor/Hedge Fund

29.28%

Individual Investor

11.65%

Hedge Fund

8.97%

Private Equity

2.85%

Research Firm

1.95%

Pension Fund

1.09%

Sovereign Wealth Fund

1.00%

Bank and Trust

0.44%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

611

28.05M

96.74%

-1.59M

2025Q2

590

32.63M

112.75%

-1.09M

2025Q1

597

32.73M

113.26%

-1.18M

2024Q4

555

33.11M

114.98%

-1.88M

2024Q3

532

33.56M

116.82%

-1.97M

2024Q2

492

34.00M

119.08%

+2.68M

2024Q1

457

29.99M

105.21%

-815.24K

2023Q4

418

29.64M

105.24%

-696.04K

2023Q3

406

29.89M

107.26%

-297.23K

2023Q2

399

29.15M

106.30%

+625.16K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

4.33M

14.95%

+13.93K

+0.32%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.52M

12.16%

-115.65K

-3.18%

Jun 30, 2025

The Vanguard Group, Inc.

2.82M

9.74%

-2.39K

-0.08%

Jun 30, 2025

Avoro Capital Advisors LLC

2.66M

9.19%

-71.00K

-2.60%

Jun 30, 2025

Krishnan (Krish S)

1.65M

5.69%

-25.00K

-1.49%

Jul 16, 2025

Krishnan (Suma M)

1.58M

5.45%

-25.00K

-1.56%

Jul 16, 2025

State Street Investment Management (US)

1.36M

4.68%

+128.64K

+10.49%

Jun 30, 2025

Soleus Capital Management, L.P.

922.96K

3.19%

+481.20K

+108.93%

Jun 30, 2025

Capital World Investors

942.25K

3.26%

-12.22K

-1.28%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

688.46K

2.38%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Franklin Genomic Advancements ETF

5.26%

First Trust NYSE Arca Biotechnology Index Fund

3.66%

Invesco S&P SmallCap Health Care ETF

3.12%

Clough Hedged Equity ETF

2.47%

Invesco S&P SmallCap 600 GARP ETF

2.31%

ALPS Medical Breakthroughs ETF

2.28%

Virtus LifeSci Biotech Products ETF

2.25%

State Street SPDR S&P Biotech ETF

2.07%

Invesco S&P SmallCap 600 Pure Growth ETF

1.54%

WisdomTree BioRevolution Fund

1.35%

Franklin Genomic Advancements ETF

占比5.26%

First Trust NYSE Arca Biotechnology Index Fund

占比3.66%

Invesco S&P SmallCap Health Care ETF

占比3.12%

Clough Hedged Equity ETF

占比2.47%

Invesco S&P SmallCap 600 GARP ETF

占比2.31%

ALPS Medical Breakthroughs ETF

占比2.28%

Virtus LifeSci Biotech Products ETF

占比2.25%

State Street SPDR S&P Biotech ETF

占比2.07%

Invesco S&P SmallCap 600 Pure Growth ETF

占比1.54%

WisdomTree BioRevolution Fund

占比1.35%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Krystal Biotech Inc的前五大股东是谁？



Krystal Biotech Inc 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：4.33M，占总股份比例：14.95%。
BlackRock Institutional Trust Company, N.A.持有股份：3.52M，占总股份比例：12.16%。
The Vanguard Group, Inc.持有股份：2.82M，占总股份比例：9.74%。
Avoro Capital Advisors LLC持有股份：2.66M，占总股份比例：9.19%。
Krishnan (Krish S)持有股份：1.65M，占总股份比例：5.69%。